Jonathan P. Foster - Oct 25, 2024 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
Chief Financial Officer
Signature
/s/ Jonathan P. Foster
Stock symbol
MBRX
Transactions as of
Oct 25, 2024
Transactions value $
$0
Form type
4
Date filed
11/6/2024, 08:00 PM
Previous filing
Jun 25, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Stock option (right to buy) Award +65K +100.25% 130K Nov 4, 2024 Common Stock 65K $2.45 Direct F1, F2
transaction MBRX Restricted Stock Units Award +82.5K +63.54% 212K Nov 4, 2024 Common Stock 82.5K Direct F2, F3, F4
transaction MBRX Performance Based Restricted Stock Units Award +19.2K +9.03% 232K Oct 25, 2024 Common Stock 19.2K Direct F2, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
F2 Issued in connection with the reporting person's employment with the Company.
F3 Each restricted stock unit represents a contingent right to receive one shares of Company common stock.
F4 The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
F5 On December 29, 2023, the Board approved this performance based restricted stock unit, subject to shareholder approval of the stock plan. The performance based restricted stock units set forth in this table will vest only upon both (A) the approval of the Plan Amendment by the Company stockholders; and (B) the first of the following to occur: (a) a licensing transaction with a valuation, at the time, in excess of $150 million, which valuation shall be determined by the Board; (b) the filing of a new drug application; or (c) upon a Change in Control (as defined in the Plan), in each case subject to the respective executive officer's continued service with the Company at each such vesting date.